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Alphaviruses are plus-strand RNA viruses that are 
transmitted by mosquitoes. There are very limited 
vaccines and treatment options available to those 
infected with alphaviruses, resulting in significant 
human and animal morbidity and mortality each 
year. Viruses are parasites of host cell metabolism and 
alphaviruses have been shown to increase glycolytic 
flux during infection to aid viral replication. Imatinib 
mesylate is an FDA-approved tyrosine kinase inhibitor 
that is used to treat several types of cancers. A hallmark 
of tumorous cells is an elevated metabolic rate and 
Imatinib successfully slows metabolism by inhibiting 
tyrosine kinases that are required to activate metabolic 
enzymes, such as hexokinase in the glycolytic pathway. 
It was hypothesized that Imatinib could be used to 
slow metabolism in virally-infected cells and reduce 
viral replication. Alphavirus-infected cells were treated 
with various concentrations of Imatinib and at a 
concentration of 6 μM, viral replication was reduced 
by more than 40% while cell viability was still at 
100%. The efficacy of Imatinib treatment at inhibiting 
alphavirus replication was confirmed at different times 
post infection (6, 12, 18, and 24 hours post infection), 
different levels of infection (multiplicities of infection= 
0.1, 1, and 10), and within different cell lines (BHK, Huh7 
and HEK). Further analysis in mouse or other animal 
models is needed to confirm the utility of Imatinib as a 
therapeutic option for treating alphavirus infection, but 
the data are promising and shows a significant reduction 
in viral replication and may represent a novel treatment 
option for alphavirus infections. 
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Alphaviruses are enveloped, plus-strand 
RNA viruses, that are transmitted via 
mosquito vectors. Alphaviruses, including 
Eastern, Western, and Venezuelan Equine 
Encephalitis Virus, Chikungunya Virus, 
Sindbis Virus, and Semliki Forest Virus, are 
responsible for millions of infections each year 
(15, 22). Chikungunya virus recently spread to 
North, South, and CentralAmerica and resulted 
in more than 2.9 million confirmed 
and suspected cases, with nearly 300 deaths as 
of summer 2016 (11, 26). Alphavirus infection 
results in a wide range of symptoms including 
rash, malaise, chronic arthralgia, and can even 
lead to fatal encephalitis (2, 23, 30). There 
are few effective treatment options available 
for those infected with alphaviruses and a 
novel method to treat and inhibit alphavirus 
infections is imperative to public health. 
Traditionally, antiviral therapies have 
been designed and engineered to target viral 
proteins, instead of host cell proteins in order 
to prevent cytotoxicity to the host cells (17). 
However, due to the rapid rate of mutation and 
diversity within viral species, viral specific 
drug treatments are limited in efficacy and 
burdened with the rapid development of drug 
resistance. New strategies involve altering or 
limiting cellular pathways that the virus relies 
on and thereby reducing the viral replication 
capacity of the host cell (4). All viruses are 
parasites of the host cell metabolic pathways 
and depend on the host cell for all biomolecule 
and energy synthesis requirements. Many 
viruses, including alphaviruses, have been 
shown to manipulate cellular metabolic 
pathways to enhance the cellular environment 
and make it optimal for viral replication (8, 9, 
19, 29). Sindbis virus (SINV) is the prototype 
alphavirus and is commonly used as the model 
virus for other alphaviruses. For Sindbis virus, 
an elevated glycolytic rate appears to benefit 
the virus replication(6). It was hypothesized 
that drugs that inhibit or reduce metabolic 
rates may effectively be used to slow and 
inhibit viral replication.  
Metabolic inhibitors have been studied 
extensively in the cancer research fields. 
Cancer is essentially a metabolic/cell division 
disorder where cells grow uncontrollably 
with an elevated metabolic rate. Many cancer 
drugs target this elevated metabolism and 
reduce or slow down metabolism to normal 
levels, thereby inhibiting cancer growth and 
metastasis (27). Due to the widespread burden 
of cancer, there has been much research in 
metabolic inhibitor drugs and there are several 
options that are FDA-approved and are used 
clinically to treat cancers (5, 10, 16).  Viral 
infections induce a similar elevated metabolic 
phenotype in host cells and some of these 
metabolic inhibitor cancer drugs have been 
repurposed as novel treatment options for viral 
infections. 
Imatinib mesylate, or Gleevec®, is a 
tyrosine kinase inhibitor that prevents 
the phosphorylation and activation of 
key enzymes in metabolic pathways (1). 
Specifically, Imatinib has been shown to 
reduce the activity of hexokinase, which is 
a key enzyme in the glycolysis pathway (3, 
18). Sindbis virus is dependent on glycolysis 
and it was predicted that inhibiting the 
glycolytic pathway would result in less viral 
replication.  We hypothesized that Imatinib 
mesylate, which is already used clinically, may 
be repurposed and effectively used to treat 
alphavirus infection. Here we present our 
findings that Imatinib mesylate successfully 
reduces Sindbis virus replication in cell culture 
at low enough concentrations that do not 
affect host cell viability. Investigating different 
Imatinib concentrations, viral titers, infection 
times, treatment addition times, and various 
cell lines have all shown Imatinib to be 
efficacious at inhibiting Sindbis virus infection. 
METHODS 
 
CELLS AND CELL CULTURE
Baby Hamster Kidney (BHK) cells 
were grown in Dulbecco’s Modified Eagle 
Medium (DMEM) media supplemented with 
streptomycin/penicillin and 10% FBS. Cells 
were incubated in T75 flasks or 24-well culture 
plates and kept in an incubator at 37ºC and 5% 
CO2. Cells were passaged every 3 days once 
85% confluent using PBS and 0.25% Trypsin. 
Cells were counted and seeded into well plates 
(24-well) 24 hours before an experiment so 
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that the cells would be about 70% confluent at 
the time of infection/treatment (75,000 BHK 
cells/ml= ~37,500 BHK cells/well).  Human 
hepatoma (Huh7) cells and Human embryonic 
kidney (HEK) cells were maintained in similar 
conditions but were passaged every 4 days. 
VIRUS AND VIRAL INFECTION
The 100 +/- 10 mg of fresh rind and curd 
saSindbis virus, which belongs to Togaviridae 
and is an old world alphavirus, was used as 
the model alphavirus for all experiments. A 
Green Fluorescent Protein (GFP) reporter was 
previously inserted into the viral genome 
via a duplicated subgenomic promoter at 
the 3’ end of the viral genome. This GFP is 
concurrently expressed with the viral proteins 
and the relative GFP fluorescence serves as a 
direct indicator for viral replication in infected 
cells. These double subgenomic alphavirus 
reporters are well established and used widely 
in the alphavirology field(21, 23, 28). Prior to 
infection, a sample well was used to count 
cells. Cells were trypsinized, resuspended, 
and counted using Trypan Blue staining and 
a hemocytometer. Once an accurate count of 
cells/well was available, the amount of virus 
could be calculated and added to the specified 
wells. Cells were infected with a multiplicity 
of infection (MOI) of 1, unless otherwise noted. 
MOI is the ratio of infectious virus particles 
(plaque forming units (PFU)) to number of 
cells and an MOI=1 will infect a majority of 
cells in the well. The corresponding amount 
of virus was added to the total volume needed 
and then was added to each well being 
infected. The plates were incubated for 1 hour 
at 37ºC to allow the virus to infect and enter 
the host cells. Following 1 hour of infection, the 
media containing the virus was removed, the 
cells were washed with PBS, and fresh media 
(with or without the treatment) was added 
to the cells. The infected cells were put back 
in the incubator and allowed to infect for the 
specified time.  
 
IMATINIB TREATMENT
Imatinib mesylate was purchased (Sigma) 
and resuspended in H2O to make a 100mM 
stock.  This 100mM stock was then serially 
diluted with two-fold dilutions to acquire 
stock concentrations at 50mM, 25mM, 12.5mM, 
6.25mM, 3.125mM, and 1.56mM. To treat the 
cells, the mM stocks were diluted 1:1000 in cell 
culture media to provide media with 100μM, 
50μM, 25μM, 12.5μM, 6.25μM, 3.125μM, and 
1.56μM concentrations of Imatinib in cell 
culture media that could be added directly to 
infected cells. A control treatment was prepared 
by diluting H2O solvent 1:1000 in media 
following the protocol as the drug dilutions. 
The dilutions of Imatinib in cell culture media 
were always prepared fresh for experiments.  
For the experiments with different times of 
Imatinib addition, the media was removed 
at the specified time and replaced with fresh 
DMEM containing the corresponding dilution 
of Imatinib or the solvent control.  
 
CYTOTOXICITY OF IMATINIB 
AND PLATE READER 
Cell viability was assessed using the 
alamarBlue Cell Viability Assay® from 
ThermoFisher according to manufacturer’s 
protocols. Briefly, Imatinib treated cells 
were stained with a concentration of 100μM 
Resazurin/alamarBlue and allowed to incubate 
for 1 hour at 37ºC. Following the one hour 
incubation, the plates were analyzed on an 
EnSpire Multimode Plate Reader ® from 
PerkinElmer for fluorescence at an excitation 
of 540-570nm and an emission of 580-610nm 
to measure the viable cells. The mock/control 
treated cells were set to 100% and then the 
viability readings from the treated wells were 
calculated as a percentage of the control. All 
experiments were performed and analyzed 
multiple times in triplicate.
QUANTIFYING VIRUS 
REPLICATION AND FLOW 
CYTOMETRY
Virus replication was quantified based 
on the GFP reporter inserted into the viral 
genome. GFP was measured in infected/treated 
cells using the plate reader (see above) and an 
excitation of 488nm and an emission filter of 
509nm. Additionally, cells were trypsinized, 
resuspended, and run over a Guava easyCyte® 
flow cytometer from Millipore to assess the 
percent of cells infected (expressing GFP) and 
the relative levels of GFP fluorescence per cell. 
5,000 cells were analyzed for each sample and 
each condition was run in triplicate. The same 
parameters, regions, thresholds, and gating was 
used for all analysis to successfully measure 
GFP positive cells. 
STATISTICAL ANALYSIS
All data graphs were generated with 
Microsoft Excel. Data and statistical analysis was 
performed using R Software. Student’s t-tests 
were performed and a p-value <0.05 indicated 
statistically significant differences. Error bars 
indicate the Standard error of the mean unless 
noted otherwise.
 
QUANTIFYING VIRUS 
REPLICATION AND FLOW 
CYTOMETRY
Baby Hamster Kidney (BHK) cells were 
infected with a double subgenomic Sindbis 
virus (SINV) containing a fluorescent 
reporter (GFP) protein inserted in the viral 
genome(21). Virus was added to the cells to 
achieve a multiplicity of infection (MOI) of 
one and after one hour of infection, Imatinib 
was added to specified wells at various low 
concentrations of Imatinib (0-100μM). After 
24 hours of infection, the cells were analyzed 
for GFP fluorescence as an indicator for 
SINV replication either with a plate reader or 
with the flow cytometer. Data from the flow 
cytometer accurately matched the data from the 
plate reader, but the flow cytometer allowed 
more specifics to be analyzed (fluorescence 
per cell and percent infected). Treatment 
of SINV-infected BHK cells with Imatinib 
showed a dose-dependent decrease in viral 
replication (Figure 1). Cytotoxicity of the 
Imatinib concentrations was also measured on 
the BHK cells using alamarBlue Cell Viability 
Assay. Imatinib started reducing cell viability 
at concentrations above 12μM, with a dose-
dependent curve of cytotoxicity at higher 
concentrations of Imatinib. Treatment with 
concentrations less than 12μM resulted in 
greater than 80% cell viability. However, at 
6μM Imatinib treatment, viral replication was 
significantly reduced by more than 50%. The 
IC50 and CC50 were calculated to be 4.8μM 
and 28.1μM, respectively, giving a therapeutic 
index of 5.85 for using Imatinib as an antiviral 
for alphaviruses. Ribavirin, which is a well-
established antiviral therapy that is used in 
severe viral infections, has a therapeutic index 
of around 5-8 for Sindbis virus, indicating 
that Imatinib treatment is equally effective at 
treating alphavirus infection(13, 20, 24).   
 
IMATINIB’S EFFECT OVER 
TIME AND DIFFERENT LEVELS 
OF SINV INFECTION
Imatinib’s effects on SINV virus replication 
over time was investigated next. Cells were 
infected with dsSINV-GFP at an MOI=1 and 
then half of the cells were left untreated and 
half of the cells were treated with 10μM 
Imatinib. Cells were analyzed every 6 hours 
for a 24 hour period to detect GFP fluorescence 
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Figure 1: Imatinib inhibition of Sindbis virus and cell viability
Flow cytometry analysis of BHK cells infected with dsSINV-GFP at an MOI=1 and treated with dilutions 
of Imatinib SINV replication (Gray bars) and cell viability (Black line) are shown with increasing 
concentrations of Imatinib. Both the mock/untreated samples were set to 100% and the different treatment 
conditions were calculated as a percentage of the mock. SINV was significantly inhibited at 6 μM of 
Imatinib compared to mock treated (p<0.05). Error bars represent standard deviation n=3.
and calculate the percentage of cells infected 
using flow cytometry. Significant inhibition of 
virus replication (Student’s t-test p<0.05) was 
seen in all time points past 12 hours that were 
treated with Imatinib (Figure 2A). Additionally, 
BHK cells were infected with an increasing 
amount of virus and then treated with mock 
solvent or 10uM Imatinib and allowed to infect 
for 24 hours. Cells were analyzed on flow 
cytometry to determine the percentage of cells 
infected (Figure 2B). Increasing the level of 
infection (multiplicity of infection= MOI) by 
up to 10 fold still showed a reduction in virus 
infection in cells treated with 10μM Imatinib 
(Figure 2B). 
 
TIME OF TREATMENT 
AFFECTS IMATINIB 
INHIBITION OF SINV
We sought to validate Imatinib as a treatment 
option by investigating different times of 
treatment and at a higher infection level 
(MOI=10). BHK cells were treated with 10μM 
Imatinib at 6 or 3 hours pre infection, at the 
same time as infection (0hrs), or 3, 6, or 12 hours 
post infection. The virus was added at time 0 
at an MOI=10 and then the cells were allowed 
to infect for 24 hours before being analyzed on 
flow cytometry. Each time point was analyzed 
and the treatment was set as a percentage of the 
untreated control (Figure 3).  
 
IMATINIB INHIBITION OF 
SINV WORKS IN MULTIPLE 
CELL TYPES
To confirm the anti-viral effect of Imatinib 
on infected cells, the study was expanded to 
include human cultured cells. Human Hepatoma 
cells (Huh7) and Human Embryonic Kidney 
cells (HEK) were utilized by being plated and 
infected with dsSINV-GFP at an MOI=10 
similar to the BHK cells. 10μM of Imatinib 
treatment successfully reduced SINV replication 
in both the Huh7 and the HEK cells at 24 hours 
post infection with an MOI=1(Figure 4). 
 
 
Imatinib mesylate, or Gleevec®, is already 
FDA-approved and is used regularly in cancer 
treatments. Clinically, Imatinib is administered 
orally at low dosages (400mg p.o. b.i.d=.800mg/
day)(5). We report that at similarly low 
concentrations (10 μM), Imatinib reduced SINV 
replication in cultured cells. This novel finding 
suggests that metabolic inhibitors used in cancer 
chemotherapy may be repurposed and used 
for treating viral infections. Imatinib mesylate 
works by inhibiting tyrosine kinases within 
the host cell(5, 18). Many metabolic enzymes 
require phosphorylation from tyrosine kinases 
in order to be activated. The general inhibition 
of tyrosine kinases reduces the ability of the 
cell to have elevated metabolic rates. This 
limitation on cellular pathways prevents the 
virus from manipulating host cell metabolism 
and hijacking certain pathways for optimal 
viral replication. During Imatinib treatment, 
the cell is maintained at lower metabolic 
rates and therefore limits the ability of the 
virus to replicate. This hypothesis has been 
validated and it has been shown that Sindbis 
virus is significantly inhibited in cells treated 
with 10μM Imatinib. This concentration of 
Imatinib was not toxic to the cells and presents 
a therapeutic window where Imatinib may 
be used effectively to limit virus replication, 
while maintaining host cell viability (Figure 
1). Imatinib’s therapeutic index was similar to 
Ribavirin, which is a clinical antiviral used 
to treat severe cases of Respiratory Syncytia 
virus (RSV)(12). Although it would be more 
advantageous if Imatinib had a higher 
therapeutic index, the proof-of-principle 
is still validated that anti-cancer and anti-
metabolism compounds may be repurposed 
and used for antivirals.  Imatinib is effective 
against Sindbis virus and investigation of other 
anti-metabolism compounds may lead to the 
discovery of an even more effective drug that 
can be used to treat viral infections. 
This Imatinib anti-viral effect was confirmed 
at different times during the virus replication 
cycle and indicates a general overall reduction 
in virus infection as compared to a step/cycle 
specific inhibition effect.  Over the course of 
24 hours, untreated cells showed a gradual 
increase in percent of SINV- infected cells 
eventually reaching about 25% infected, which 
is statistically significant when compared to the 
Imatinib treated cells that only reached about 
5% of cells infected at 24 hours. Significant 
reduction in virus replication was seen in a 
wide variety of infection levels, as indicated by 
different infection MOI’s (Figure 2). Interestingly, 
the plates that were examined at different time 
points showed higher infection levels (up to 
25%) compared to the MOI plates (only up to 
about 17%). This may be due to the fact that the 
time course plates were physically moved every 
6 hours, which would result in a disruption 
of the media and may have redistributed the 
virus supernatant throughout the culture. These 
results imply that Imatinib may be successfully 
used to reduce viral loads at different times and 
levels of infection. 
To further assess the efficacy of Imatinib to 
lower viral replication, the impact of treatment 
timing on viral infection was investigated.  
Understanding the opportune timing for 
treatment is a critical component for antivirals 
to discover if the compound is more effective 
if given prophylactically prior to exposure or if 
post-infection treatment is more effective. The 
greatest inhibition of virus replication was seen 
in cells that received the Imatinib treatment 
3 or 6 hours prior to infection. Adding the 
Imatinib at the same time as infection or up 
to 3 hours post infection still achieved about a 
20% reduction in virus replication, but adding 
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Figure 2: Imatinib treatment at different times post-infection and SINV concentrations
A) SINV-infected BHK cells (MOI=1) were treated with 10μM Imatinib (dotted line) or left untreated (black 
line) and analyzed every 6 hours for the percentage of cells infected using flow cytometry. B) BHK cells 
infected with increasing amounts of virus and treated with 10 μM Imatinib (gray) or left untreated (black). 
The percentage of cells infected was determined with flow cytometry at 24 hours. Significant reductions 
(Students T-test P<0.05) in dsSINV-GFP replication are indicated with an asterisk (*).
Figure 3: Treatment with Imatinib at different treatment times
BHK cells were treated with 10 μM Imatinib or solvent control at the times indicated and dsSINV-GFP 
(MOI=10) was added at time 0.  At 24 hours post infection, the cells were analyzed for dsSINV-GFP via 
flow cytometry. The untreated sample for each condition was set to 100%. The greatest difference was seen 
with a single treatment.
Figure 4: A) Human hepatoma (Huh7) and B) Human embryonic kidney (HEK) cells were infected with 
dsSINV-GFP at an MOI=10 and then treated with 10 μM Imatinib or solvent control (untreated). At 24 
hours post infection, the cells were analyzed for dsSINV-GFP via flow cytometry. All data is displayed as a 
percentage of the untreated samples. (n=6).
the Imatinib 6 hours or later after infection did 
not result in a significant inhibition of virus 
infection (Figure 3). The 20% reduction is not 
as significant as what was seen in previous 
experiments, but that is likely due to the higher 
MOI and also greater movement of the plate 
during the infection incubation. Pre-infection 
treatment with Imatinib reduced the virus 
replication more effectively than treatments that 
were added concurrently or post infection. This 
indicates that Imatinib may be most effective 
as a prophylactic drug, given prior to high 
risk exposure situations. However, due to the 
inherent side effects of anti-cancer and anti-
metabolic drugs, prophylactic treatment might 
not be feasible in a clinical setting, but post-
infection treatment may be effective. Although 
not as significant as a pre-infection treatment, 
even treating with Imatinib at 3 hours post-
infection successfully reduced virus infection 
and confirms the potential utility of using 
Imatinib as a post-exposure/infection treatment 
option (Figure 3). 
The Imatinib inhibition of SINV infection 
was further confirmed in human cultured 
cells, both liver (Huh7) and kidney cells 
(HEK), which both showed a similar 
reduction in virus replication as was observed 
in the BHK cells (Figure 4). Huh7 and HEK 
cells are common cell lines used in virology 
to assess virus replication in human tissue 
and it is promising that both cell lines show 
an effective reduction in SINV replication 
when treated with 10μM Imatinib.  Variation 
in viral reduction is likely due to specific 
differences in the cell type, but the overall 
trend of viral inhibition with Imatinib 
treatment is maintained in the different 
human cell lines. This validates the potential 
efficacy of using Imatinib as a therapeutic 
anti-viral treatment option in human 
alphavirus infections.  
In this study, a single metabolic inhibiting 
cancer drug known as Imatinib mesylate 
was investigated. Imatinib has shown very 
promising inhibition of Sindbis virus 
replication at different times, levels/MOI’s, 
and host cells. Further work will be done 
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